The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Future of the lymphoma field
Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape of lymphoma, including recent data evaluating allogeneic CAR T-cells in the relapsed/refractory setting. Furthermore, the development of novel targeted agents such as tafasitamb, as evaluated in the Phase II L-MIND study (NCT02399085), represents an exciting approach in the lymphoma field. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
